Form D · Biotechnology
Metsera, Inc.
New York, NY · CIK 0002040807
Offering snapshot reported Nov 20, 2024 · SEC filing
- Reported sold
- $215M Offering amount: $215M
- Investors reported
- 38 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 12, 2024 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 20, 2024 | Initial | $214,999,939 | No comparison | 38 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-529922
Source: Form D, filed Nov 20, 2024. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Christopher Whitten Bernard | Director, Executive |
| Paul L. Berns | Director |
| Kristina Burow | Director |
| Brian Hubbard | Executive |
| Steven Marso | Executive |
| Clive A. Meanwell | Director |
| Joshua Pinto | Director |
| Christopher J. Visioli | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3 World Trade Center 175 Greenwich Street
New York, NY, 10007
New York, NY, 10007